Immunic | VTL - Gross Profit On Sales


Immunic reported 0 in Gross Profit on Sales for its fiscal quarter ending in March of 2025.





Gross Profit On Sales Change Date
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Cipla INR 41.64B 6.31B Dec/2025
Clal Biotechnology ILS -857K 1.42M Jun/2022
Compugen USD 63.8M 63.56M Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Enanta Pharmaceuticals -22.29M 23.75M Dec/2024
Grifols EUR 766.49M 39.74M Dec/2024
Immunic 0 0 Mar/2025
Insmed USD 217.69M 106.25M Dec/2025
Omeros USD -33.16M 18.52M Jun/2024
OraSure Technologies USD 11.34M 435K Dec/2025
Quidel USD -91.8M 366.6M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
United Therapeutics USD 315.5M 286.6M Dec/2025
Xoma 992K 846K Jun/2024